Central Role For Industry Beckons As Europe Rebuilds After COVID
Generics And Biosimilars Must Become A Central Policy Pillar, Says Rebecca Guntern
Executive Summary
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.